R. Tartarini

Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.

E. Giovannetti, R. Danesi, M. del Tacca, 2009, Anticancer research.

Model-Based Dialysis Adequacy Prediction by Continuous Dialysate Urea Monitoring

A. Cappello, L. Chiari, F. Paolini, 1998, The International journal of artificial organs.

Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.

D. Pezzuolo, M. Cantore, T. Torri, 2009, Anticancer research.

A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma

E. Giovannetti, G. Peters, F. Crea, 2013, Oncology letters.

Nutritional counseling.

M. Muttini, P. Pacetti, A. Mambrini, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pet therapy effects on oncological day hospital patients undergoing chemotherapy treatment.

Andrea Mambrini, Paola Pacetti, Massimo Orlandi, 2007, Anticancer research.

Low Dose Fractionated Cisplatin Plus Gemcitabine for Elderly Patients with Advanced Non Small Cell Lung Cancer: A Retrospective Analysis

D. Pezzuolo, M. Cantore, P. Pacetti, 2010, Journal of chemotherapy.

Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer

M. Besselink, A. Frampton, H. V. van Laarhoven, 2024, The Journal of Liquid Biopsy.